Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases (NCT07437820) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases
France68 participantsStarted 2026-07
Plain-language summary
The purpose of this study is to evaluate the local control rate on the target lesion at 6, 12, and 24 months after treatment with neoadjuvant stereotactic radiotherapy (SRS NEO group) compared to standard care, adjuvant stereotactic radiotherapy (POST OP SRS group).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged 18 years and older;
* Patients with 1 to 12 brain metastases on preoperative MRI, at least one of which (contrast enhancement of at least 1 cm) is accessible for the most complete possible resection (target lesion);
* Patients with a Karnofsky performance score of ≥ 70;
* Patients able to perform neurocognitive tests without assistance;
* Patients who understand the study and agree to attend all visits;
* Patients who have signed a written informed consent form;
* Affiliation with a social security system.
Exclusion Criteria:
* Patient who has already been treated with surgery, radiosurgery, and/or radiotherapy for the target brain metastasis;
* Medical contraindication to MRI;
* Patient with an estimated life expectancy of ≤ 3 months;
* Patients participating in another clinical trial, or who are in the exclusion period of another clinical trial;
* Patients unable to complete a self-administered questionnaire;
* Patients from a vulnerable population.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial compares giving stereotactic radiotherapy before surgery versus after surgery for brain metastases — can you walk me through how each approach might affect my specific situation, and which one you'd lean toward outside of a trial?
2Since this trial isn't recruiting yet, how long do you expect it might be before it opens, and is there a standard-of-care option I should be considering in the meantime rather than waiting?
3The trial's main goal is measuring local control — meaning whether the treated tumor comes back in the same spot — so what does that tell us about what the study can and can't tell me about overall survival or quality of life?
4This trial is listed as Phase NA, which can mean it's a design or feasibility study rather than a traditional efficacy trial — does that change how much we'd know about safety and benefit compared to a more typical Phase 2 or 3 study?
5Given that I have brain metastases, are there other active or already-enrolling trials comparing these same timing approaches that might be worth looking at while this one is still getting started?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Local control rate of the target lesion
Timeframe: 6 months
2
Local control rate of the target lesion
Timeframe: 12 months
3
Local control rate of the target lesion
Timeframe: 24 months
Trial details
NCT IDNCT07437820
SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche